BRIEF published on 12/23/2024 at 22:10, 1 year 2 months ago Abivax Announces Board Resignation Abivax Obefazimod Board Resignation Truffle Capital Philippe Pouletty
PRESS RELEASE published on 12/23/2024 at 22:05, 1 year 2 months ago Abivax Announces a Change to the Composition of its Board of Directors Abivax announces a change in its Board of Directors composition as Dr. Philippe Pouletty resigns due to new appointment. The company expresses gratitude for his contributions Board Of Directors Resignation Abivax Therapeutics Dr. Philippe Pouletty
BRIEF published on 12/18/2024 at 18:05, 1 year 3 months ago ABIVAX: Share capital and voting rights as of November 30, 2024 Euronext Paris Share Capital Voting Rights Abivax Investment
BRIEF published on 11/27/2024 at 18:05, 1 year 3 months ago ABIVAX: Update of Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights Abivax Financial Transparency
BRIEF published on 11/19/2024 at 22:35, 1 year 3 months ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 1 year 3 months ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 1 year 4 months ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE published on 11/14/2024 at 22:01, 1 year 4 months ago Abivax presents third quarter 2024 key financial information Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
BRIEF published on 11/13/2024 at 22:06, 1 year 4 months ago Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor Biotechnology Abivax Obefazimod Appointment Mark Stenhouse
PRESS RELEASE published on 11/13/2024 at 22:01, 1 year 4 months ago Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax appoints Mark Stenhouse, former Prometheus COO, as Board Observer & Advisor, bringing extensive biopharma experience to support clinical therapeutics development Abivax Mark Stenhouse Prometheus Board Observer Clinical Therapeutics
Published on 03/19/2026 at 14:20, 57 minutes ago CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/19/2026 at 13:50, 1 hour 27 minutes ago Predictiv AI Appoints Multi-Agent Systems Pioneer Professor George Rzevski as Strategic Advisor to Advance Swarm AI Platforms
Published on 03/19/2026 at 13:30, 1 hour 47 minutes ago Hillcrest Energy Technologies CEO Don Currie Discusses ZVS Technology and Commercialization Progress in Stocks To Watch Investor Interview
Published on 03/19/2026 at 13:30, 1 hour 47 minutes ago ACCESS Newswire Reports Fourth Quarter and Full Year 2025 Results
Published on 03/19/2026 at 13:15, 2 hours 2 minutes ago Worksport Presents New Premium "Game Changer" Tonneau Cover Model to Industry Buyers at Keystone BIG Show; Initiates Pre-Orders Ahead of Near-Term Commercial Launch
Published on 03/19/2026 at 15:02, 15 minutes ago Knorr-Bremse proposes higher dividend – € 1.90 per share planned
Published on 03/19/2026 at 15:00, 17 minutes ago SMT Scharf AG continues advancing its Strategy 2026 to expand the sales regions and product portfolio for business growth
Published on 03/19/2026 at 14:51, 26 minutes ago BeNEX opts for IVU.rail as its central IT system for operational planning
Published on 03/19/2026 at 14:30, 47 minutes ago Surya Roshni Strengthens Germany Footprint with Successful Showcase at Light + Building 2026
Published on 03/19/2026 at 14:16, 1 hour 1 minute ago From Kontron's point of view, current price distortions have no basis in Kontron's operating performance
Published on 03/19/2026 at 08:45, 6 hours 32 minutes ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 8 hours 17 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 8 hours 17 minutes ago 2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 19 hours 36 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
